BioSante Pharmaceuticals Inc. (BPAX) Income Statement

Income Statement for BioSante Pharmaceuticals Inc.  (BPAX) 
$ 0.851   -0.0441 (-4.93%) Volume: 7 m 4:00 PM EST Feb 10, 2012
After Hours:  $ 0.87   0.019 (+2.23%) Volume: 41.03 k 7:02 PM EST Feb 10, 2012
Statement: View:
Income [+] in Thousands of Dollars
12/2010 12/2009 12/2008 12/2007 12/2006
Operating Revenue 2,474 1,258 3,781 493 14,439
Total Revenue 2,474 1,258 3,781 493 14,439
Adjustments to Revenue - - - - -
Cost of Revenue (269) (300) - - -
Cost of Sales With Depreciation 269 300 - - -
Gross Margin 2,205 958 3,781 493 14,439
Gross Operating Profit 2,205 958 3,781 493 14,439
Selling/General/Admin Expense (5,940) (5,374) (5,961) (4,331) (7,025)
Research & Development (39,706) (13,681) (15,790) (4,751) (3,856)
Advertising - - - - -
EBITDA (Operating Income Before Depreciation) (43,440) (18,096) (17,971) (8,590) 3,558
Depreciation & Amortization (168) (137) (43) (90) (118)
Depreciation, Unreconciled 168 137 43 90 118
Amortization - - - - -
Amortization of Intangibles - - - - -
Operating Income (43,608) (18,233) (18,014) (8,679) 3,440
Operating Profit After Depreciation (43,608) (18,233) (18,014) (8,679) 3,440
Interest Income 13 12 588 1,095 428
Earnings from Equity Interest - - - - -
Other Income, Net (1,912) (20,159) - - -
Income, Acquired in Process R&D - (9,000) - - -
Income, Restructuring and M&A - - - - -
Other Special Charges - - - - (1,077)
Total Income Before Interest Expense (EBIT) (45,508) (47,381) (17,425) (7,584) 2,791
Interest Expense (688) (147) - - -
Income Before Tax (46,196) (47,528) (17,425) (7,584) 2,791
Income Taxes - - - - -
Minority Interest - - - - -
Preferred Securities of Subsidiary Trust - - - - -
Other Special Charges - - - - -
Net Income from Continuing Operations (46,196) (47,528) (17,425) (7,584) 2,791
Net Income from Discontinued Operations - - - - -
Net Income from Total Operations (46,196) (47,528) (17,425) (7,584) 2,791
Normalized Income (46,196) (38,528) (17,425) (7,584) 3,868
Extraordinary Income/Loss - - - - -
Special Income/Charges - (9,000) - - (1,077)
Income from Cum. Effect of Acct Change - - - - -
Income from Tax Loss Carryforward - - - - -
Net Income Available for Common (46,196) (47,528) (17,425) (7,584) 2,791
Other Gains - - - - -
Total Net Income (46,196) (47,528) (17,425) (7,584) 2,791
Net Income Available for Common (46,196) (47,528) (17,425) (7,584) 2,791
Results [+] in Dollars (Preferred Dividends in Thousands)
12/2010 12/2009 12/2008 12/2007 12/2006
Dividends Paid Per Share 0.00 0.00 0.00 0.00 0.00
Preferred Dividends - - - - -
Basic EPS from Continuing Operations -0.70 -1.40 -0.64 -0.30 0.13
Basic EPS from Discontinued Operations 0.00 0.00 0.00 0.00 0.00
Basic EPS from Extraordinary Income Gains/Losses 0.00 0.00 0.00 0.00 0.00
Basic EPS from Cumulative Effect of Accounting Change 0.00 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryforward 0.00 0.00 0.00 0.00 0.00
Basic EPS from Other Gains/Losses 0.00 0.00 0.00 0.00 0.00
Basic EPS from Total Net Income -0.70 -1.40 -0.64 -0.30 0.13
Basic Normalized Net Income per Share -0.70 -1.13 -0.64 -0.30 0.18
Basic EPS from Total Operations -0.70 -1.40 -0.64 -0.30 0.13
Diluted EPS from Continuing Operations -0.70 -1.40 -0.64 -0.30 0.13
Diluted EPS from Discontinued Operations 0.00 0.00 0.00 0.00 0.00
Diluted EPS from Extraordinary Gains/Losses 0.00 0.00 0.00 0.00 0.00
Diluted EPS from Cumulative Effect of Accounting Change 0.00 0.00 0.00 0.00 0.00
Diluted EPS from Tax Loss Carryforward 0.00 0.00 0.00 0.00 0.00
Diluted EPS from Other Gains/Losses 0.00 0.00 0.00 0.00 0.00
Diluted EPS from Total Net Income -0.70 -1.40 -0.64 -0.30 0.13
Diluted Normalized Net Income per Share -0.70 -1.13 -0.64 -0.30 0.18
Excise Tax - - - - -
Diluted EPS from Total Operations -0.70 -1.40 -0.64 -0.30 0.13